Sudeep Pharma’s strong stock market debut turned into an early rally, with shares gaining up to 8% after listing at a nearly 24% premium to the IPO price. The Rs 895 crore issue drew heavy demand across all investor categories, reflecting confidence in the company’s position in speciality pharma ingredients. While analysts see long-term potential backed by high margins and strong export presence, they advise caution on near-term risks such as margin pressure and raw material volatility, suggesting partial profit booking with a disciplined stop-loss.